Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q1 FY23 results · Apr–Jun 2022
Sun Pharma Advanced Research Company reported revenue from operations of ₹28.46 crore (up 29.4% from Q1 FY22) and net loss of ₹82.35 crore for Q1 FY23 (Apr–Jun 2022), on a standalone basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 28.46 | 21.99 | +29.4% | 25.24 | +12.8% |
| Other income | 0.18 | 0.80 | −77.5% | 0.22 | −18.2% |
| Total income | 28.64 | 22.79 | +25.7% | 25.46 | +12.5% |
| Profit before tax | (82.35) | (61.37) | Loss widened | (71.05) | Loss widened |
| Net profit for the period | (82.35) | (61.37) | Loss widened | (71.05) | Loss widened |
| EPS, basic (₹) | (3.03) | (2.34) | Loss widened | (2.69) | Loss widened |
| Net margin (%) | -289.4 | -279.1 | -281.5 |
Standalone
- Filed with BSE
- 09 Aug 2022, 15:23 IST
- Board meeting
- 08 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE